Tumoral Vitamin D Synthesis by CYP27B1 1-α-Hydroxylase Delays Mammary Tumor Progression in the PyMT-MMTV Mouse Model and Its Action Involves NF-κB Modulation.
暂无分享,去创建一个
W. Muller | B. Ochietti | R. Kremer | R. St-Arnaud | T. Reinhardt | A. Camirand | Aimée-Lee Luco | I. Fadhil | Jiarong Li
[1] W. Muller,et al. Chemoprevention Activity of 25-Hydroxyvitamin D in the MMTV-PyMT Mouse Model of Breast Cancer , 2014, Cancer Prevention Research.
[2] A. Lykkesfeldt,et al. 1α,25-Dihydroxyvitamin D3 inhibits cell growth and NFκB signaling in tamoxifen-resistant breast cancer cells , 2014, Steroids.
[3] Jing-quan Li,et al. Review: the impacts of circulating 25-hydroxyvitamin D levels on cancer patient outcomes: a systematic review and meta-analysis. , 2014, The Journal of clinical endocrinology and metabolism.
[4] I. Reid,et al. The effect of vitamin D supplementation on skeletal, vascular, or cancer outcomes: a trial sequential meta-analysis. , 2014, The lancet. Diabetes & endocrinology.
[5] Jie Du,et al. Vitamin D Receptor Inhibits Nuclear Factor κB Activation by Interacting with IκB Kinase β Protein* , 2013, The Journal of Biological Chemistry.
[6] L. Verlinden,et al. Antineoplastic effects of 1,25(OH)2D3 and its analogs in breast, prostate and colorectal cancer. , 2013, Endocrine-related cancer.
[7] Abena B. Redwood,et al. BRCA1 loss activates cathepsin L–mediated degradation of 53BP1 in breast cancer cells , 2013, The Journal of cell biology.
[8] John H. White,et al. Vitamin D receptor as a master regulator of the c-MYC/MXD1 network , 2012, Proceedings of the National Academy of Sciences.
[9] W. Muller,et al. PTHrP drives breast tumor initiation, progression, and metastasis in mice and is a potential therapy target. , 2011, The Journal of clinical investigation.
[10] S. Ghosh,et al. Crosstalk in NF-κB signaling pathways , 2011, Nature Immunology.
[11] A. Brożyna,et al. Expression of vitamin D receptor decreases during progression of pigmented skin lesions. , 2011, Human pathology.
[12] Peizhan Chen,et al. Meta-analysis of vitamin D, calcium and the prevention of breast cancer , 2010, Breast Cancer Research and Treatment.
[13] M. Karin,et al. Dangerous liaisons: STAT3 and NF-kappaB collaboration and crosstalk in cancer. , 2010, Cytokine & growth factor reviews.
[14] Shanling Xu,et al. The NF-κB activation pathways, emerging molecular targets for cancer prevention and therapy , 2010, Expert opinion on therapeutic targets.
[15] Hua Yu,et al. STATs in cancer inflammation and immunity: a leading role for STAT3 , 2009, Nature Reviews Cancer.
[16] M. Friedrich,et al. 25-Hydroxyvitamin D3 1alpha-hydroxylase splice variants in benign and malignant ovarian cell lines and tissue. , 2009, Anticancer research.
[17] E. Bertone-Johnson. Vitamin D and breast cancer. , 2009, Annals of epidemiology.
[18] N. Weigel,et al. 1Alpha,25-dihydroxyvitamin D3 reduces c-Myc expression, inhibiting proliferation and causing G1 accumulation in C4-2 prostate cancer cells. , 2009, Endocrinology.
[19] E. Sarchielli,et al. The vitamin D receptor agonist elocalcitol inhibits IL‐8‐dependent benign prostatic hyperplasia stromal cell proliferation and inflammatory response by targeting the RhoA/Rho kinase and NF‐kB pathways , 2009, The Prostate.
[20] D. Deb,et al. 1,25-Dihydroxyvitamin D3 suppresses high glucose-induced angiotensinogen expression in kidney cells by blocking the NF-{kappa}B pathway. , 2009, American journal of physiology. Renal physiology.
[21] C. Ulrich,et al. Vitamin D insufficiency in a multiethnic cohort of breast cancer survivors. , 2008, The American journal of clinical nutrition.
[22] D. Trump,et al. Vitamin D signalling pathways in cancer: potential for anticancer therapeutics , 2007, Nature Reviews Cancer.
[23] J. Reichrath,et al. 25-Hydroxyvitamin D3 1alpha-hydroxylase splice variants in breast cell lines MCF-7 and MCF-10. , 2007, Cancer genomics & proteomics.
[24] R. Recker,et al. Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial. , 2007, The American journal of clinical nutrition.
[25] Zhiyuan Hu,et al. Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors , 2007, Genome Biology.
[26] Y. Suárez,et al. Vitamin D regulates the phenotype of human breast cancer cells. , 2007, Differentiation; research in biological diversity.
[27] D. Notterman,et al. Gene expression profiling changes induced by a novel Gemini Vitamin D derivative during the progression of breast cancer. , 2006, Biochemical pharmacology.
[28] M. Campbell,et al. Vitamin D status and breast cancer risk. , 2006, Anticancer research.
[29] E. Kallay,et al. Nutrients regulate the colonic vitamin D system in mice: relevance for human colon malignancy. , 2006, The Journal of nutrition.
[30] R. Benya,et al. Expression of Vitamin D Receptor and 25-Hydroxyvitamin D3-1α-Hydroxylase in Normal and Malignant Human Colon , 2005, Cancer Epidemiology Biomarkers & Prevention.
[31] J. Welsh,et al. Vitamin D receptor (VDR) ablation alters carcinogen-induced tumorigenesis in mammary gland, epidermis and lymphoid tissues , 2005, The Journal of Steroid Biochemistry and Molecular Biology.
[32] M. Guy,et al. Autocrine Metabolism of Vitamin D in Normal and Malignant Breast Tissue , 2005, Clinical Cancer Research.
[33] M. Holick. Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease. , 2004, The American journal of clinical nutrition.
[34] J. Welsh,et al. Vitamin D receptor status alters mammary gland morphology and tumorigenesis in MMTV-neu mice. , 2004, Carcinogenesis.
[35] M. Willingham,et al. Pancreatic cancer cells express 25-hydroxyvitamin D-1α-hydroxylase and their proliferation is inhibited by the prohormone 25-hydroxyvitamin D3 , 2004 .
[36] I. Ellis,et al. Expression of luminal and basal cytokeratins in human breast carcinoma , 2004, The Journal of pathology.
[37] Jeffrey B. Cheng,et al. Genetic evidence that the human CYP2R1 enzyme is a key vitamin D 25-hydroxylase. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[38] P. Tuohimaa,et al. 25‐Hydroxyvitamin D3 is an active hormone in human primary prostatic stromal cells , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[39] Jeffrey W Pollard,et al. Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases. , 2003, The American journal of pathology.
[40] M. Holick. Vitamin D: A millenium perspective , 2003, Journal of cellular biochemistry.
[41] J. Rhim,et al. Targeted Disruption of the 25-Hydroxyvitamin D3 1α-Hydroxylase Gene in ras-Transformed Keratinocytes Demonstrates That Locally Produced 1α,25-Dihydroxyvitamin D3 Suppresses Growth and Induces Differentiation in an Autocrine Fashion11 Canadian Institutes of Health Research Grant MT10839 (to R.K.). , 2002 .
[42] R. Glazer,et al. Delayed mammary gland involution in MMTV-AKT1 transgenic mice , 2002, Oncogene.
[43] L. Hennighausen,et al. Spatial and temporal expression of the Cre gene under the control of the MMTV-LTR in different lines of transgenic mice , 2001, Transgenic Research.
[44] R. Kremer,et al. Calcitroic Acid Is a Major Catabolic Metabolite in the Metabolism of 1α-Dihydroxyvitamin D2 , 2001 .
[45] J. Welsh,et al. Functions of 1α,25-dihydroxyvitamin D3 in mammary gland: from normal development to breast cancer , 2001, Steroids.
[46] M. Hakama,et al. Prostate cancer risk and prediagnostic serum 25-hydroxyvitamin D levels (Finland) , 2000, Cancer Causes & Control.
[47] N. Bundred,et al. 1α,25-Dihydroxyvitamin D3 Inhibits Angiogenesis In Vitro and In Vivo , 2000 .
[48] W. Kuo,et al. Quantitative mapping of amplicon structure by array CGH identifies CYP24 as a candidate oncogene , 2000, Nature Genetics.
[49] M. Rudnicki,et al. Amplification of the neu/erbB-2 oncogene in a mouse model of mammary tumorigenesis. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[50] V. Soldatenkov,et al. Novel 19-nor-hexafluoride vitamin D3 analog (Ro 25-6760) inhibits human colon cancer in vitro via apoptosis. , 1999, International journal of oncology.
[51] C. Glass,et al. Coactivator and corepressor complexes in nuclear receptor function. , 1999, Current opinion in genetics & development.
[52] H. Matsumoto,et al. Antitumor effect of 22-oxacalcitriol on estrogen receptor-negative MDA-MB-231 tumors in athymic mice. , 1999, Oncology reports.
[53] A. Mackay,et al. Effects of 1,25 dihydroxyvitamin D3 and its analogues on induction of apoptosis in breast cancer cells , 1996, The Journal of Steroid Biochemistry and Molecular Biology.
[54] R. Evans,et al. The RXR heterodimers and orphan receptors , 1995, Cell.
[55] N. Brünner,et al. 1α,25-Dihydroxyvitamin D3 inhibits the invasive potential of human breast cancer cellsin vitro , 1994, Clinical & Experimental Metastasis.
[56] G. Schwartz,et al. Geographic patterns of prostate cancer mortality. Evidence for a protective effect of ultraviolet radiation , 1992, Cancer.
[57] J. Rhim,et al. Relative resistance to 1,25-dihydroxyvitamin D3 in a keratinocyte model of tumor progression. , 1992, The Journal of biological chemistry.
[58] T. Pepersack,et al. Calcium and vitamin D metabolism in granulomatous diseases , 1992, Clinical Rheumatology.
[59] R. Cardiff,et al. Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease , 1992, Molecular and cellular biology.
[60] J. F. Young,et al. Geographic variation in breast cancer mortality in the United States: a hypothesis involving exposure to solar radiation. , 1990, Preventive medicine.
[61] C. Garland,et al. SERUM 25-HYDROXYVITAMIN D AND COLON CANCER: EIGHT-YEAR PROSPECTIVE STUDY , 1989, The Lancet.
[62] D. Deb,et al. 1 , 25-Dihydroxyvitamin D 3 suppresses high glucose-induced angiotensinogen expression in kidney cells by blocking the NF-B pathway , 2009 .
[63] N. Weigel,et al. 1,25(OH)2D3 reduces c-Myc expression, inhibiting proliferation and causing G1 accumulation in C4-2 prostate cancer cells. , 2009 .
[64] A. Douvdevani,et al. Vitamin D decreases NFkappaB activity by increasing IkappaBalpha levels. , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[65] A. Mercurio,et al. Mobilization and activation of a signaling competent alpha6beta4integrin underlies its contribution to carcinoma progression. , 2005, Cancer metastasis reviews.
[66] J. Welsh,et al. Comparative effects of 1,25(OH)2D3 and EB1089 on cell cycle kinetics and apoptosis in MCF-7 breast cancer cells , 2004, Breast Cancer Research and Treatment.
[67] M. Brentani,et al. Antiproliferative effects of 1,25-dihydroxyvitamin D3 on breast cells: a mini review. , 2002, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.
[68] F. Glorieux,et al. Targeted inactivation of the 25-hydroxyvitamin D(3)-1(alpha)-hydroxylase gene (CYP27B1) creates an animal model of pseudovitamin D-deficiency rickets. , 2001, Endocrinology.
[69] N. Bundred,et al. 1 alpha,25-dihydroxyvitamin D(3) inhibits angiogenesis in vitro and in vivo. , 2000, Circulation research.
[70] J. Keski‐Oja,et al. 1 a , 25-Dihydroxyvitamin D 3 and Its Analogues DownRegulate Cell Invasion-associated Proteases in Cultured Malignant Cells 1 , 2000 .
[71] M. Haussler,et al. The vitamin D hormone and its nuclear receptor: molecular actions and disease states. , 1997, The Journal of endocrinology.
[72] N. Brünner,et al. 1 alpha,25-Dihydroxyvitamin D3 inhibits the invasive potential of human breast cancer cells in vitro. , 1994, Clinical & experimental metastasis.
[73] B. Roos,et al. Concurrent measurement of plasma levels of vitamin D3 and five of its metabolites in normal humans, chronic renal failure patients, and anephric subjects. , 1981, The Journal of laboratory and clinical medicine.